Autopsy report · NCT01546571

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

“After interim analysis the study was halted to redesign a pivotal trial.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 9 years 2 months before it stopped.
• 504 participants enrolled.
• Results were posted on the registry 4 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Polynoma LLC

Sponsor type

Industry

Conditions

Melanoma

Interventions

POL-103A; POL-103A without API

Participants

504

Sites

65

Countries

Canada, United States

Trials that died the same way

• A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections
  “Study was stopped following interim analysis.” (79% match in meaning)
• Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
  “The trial was stopped based on the assessment of clinical data.” (79% match in meaning)
• Phase II Study of TAEST16001 in Soft Tissue Sarcoma
  “The study was terminated due to initiation of a new clinical trial with an updated study design.” (78% match in meaning)
• Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
  “The trial was stopped earlier than planned after an ad hoc interim analysis” (77% match in meaning)
• A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults
  “The trial was terminated early due to regulatory constraints preventing the continuation of study conduct.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.